RESUMEN
Background: The diagnosis of small bowel diseases is challenging and device assisted enteroscopy (DAE) is a technique for visualizing the entire small bowel. DAE is considered as a safe procedure and the reported rate of adverse events associated with DAE in the literature is low. Objective: The present study tried to investigate the actual incidence of AP after DAE with a systematic review and meta-analysis of available relevant studies. Methods: Studies were searched through the PubMed, EMBASE, and Cochrane library databases. The following data were extracted from all eligible studies: author, country, publication year, publication type, study design, type of DAE used, route of DAE, number of patients with AP after DAE, and number of patients with hyperamylasemia after DAE.A random-effects model with RStudio version 4.2.0 was performed in all analyses. Heterogeneity was assessed using the I2 test. The risk of bias was assessed by the Newcastle-Ottawa Scale criteria and the publication bias was assessed by the Egger test. Results: Twenty three studies involving a total of 11145 patients were included in the analysis. The overall, pooled AP rate after DAE was 1% (95% CI:0-1%). There was significant heterogeneity among the studies (I2 = 65%; P < 0.01).The pooled AP rate was 1% (95% CI:0-2 %)in peroral route group. The pooled proportion of patients having hyperamylasemia after DAE was 29% (95% CI: 16-46%).Among the patients who had hyperamylasemia AP were identified in 2% (95% CI: 0-6%) of patients. Conclusion: The incidence of AP after DAE is about 1%. Hyperamylasemia is a common change in the patients undergoing DAE and only 2% of the patients with hyperamylasemia present with AP.
Asunto(s)
Hiperamilasemia , Pancreatitis , Humanos , Pancreatitis/epidemiología , Pancreatitis/etiología , Hiperamilasemia/epidemiología , Hiperamilasemia/etiología , Hiperamilasemia/diagnóstico , Incidencia , Enfermedad Aguda , Endoscopía Gastrointestinal/efectos adversos , Endoscopía Gastrointestinal/métodosRESUMEN
BACKGROUND: The association between postoperative serum hyperamylasaemia (POH) and morbidity has been hypothesized but rarely explored once occurring with or without (POH-exclusive) a combined postoperative pancreatic fistula (POPF). METHODS: Analysis of patients who consecutively underwent pancreaticoduodenectomy from 2016 to 2020. POH was defined as serum amylase activity greater than the institutional upper limit of normal (52 U/L), persisting within the first 48 hours postoperatively (postoperative day [POD] 1 and 2). RESULTS: Among 852 patients, 15.8% developed POH-exclusive. Compared with patients without POH or POPF (64.3%), they showed a significantly higher postoperative burden (Clavien-Dindo ≥II: 52.6% vs 30.8%) with increased rates of bacteraemia (12.6% vs 6%), pleural effusion (13.3% vs 5.3%), postpancreatectomy haemorrhage (13.3% vs 7.5%), postpancreatectomy acute pancreatitis (PPAP) (10.3% vs 0%), and organ site infections (18.5% vs 10.9%; all P < .05). A total of 13.8% experienced POH with POPF leading to the worse outcome. The combined occurrence of POH with POPF led to a shorter median time to morbidity (3 PODs, 95% confidence interval [CI] 2.2-3.7 vs 6 PODs, 95% CI 4.2-8; P < .001) than patients experiencing POPF-exclusive (5.9%). In all, 46.6% of POH patients developed POPF. Body mass index (BMI) (odds ratio [OR] 1.1), male sex (OR 2.1), increased drain fluid amylase on POD 1 (OR 1.001), and increased C-reactive protein (OR 1.01) were independent risk factors for POPF once POH has occurred. CONCLUSION: POH has relevant postoperative clinical implications, independently from POPF occurrence. Developing POH with POPF leads to an earlier onset of higher postoperative burdens. Once POH is diagnosed, risk factors for additional POPF could identify patients who may benefit from additional surveillance, specific drains protocols, and preventive strategies.
Asunto(s)
Hiperamilasemia , Pancreatitis , Enfermedad Aguda , Amilasas/metabolismo , Drenaje/efectos adversos , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/epidemiología , Hiperamilasemia/etiología , Masculino , Morbilidad , Fístula Pancreática/diagnóstico , Fístula Pancreática/epidemiología , Fístula Pancreática/etiología , Pancreaticoduodenectomía/efectos adversos , Pancreatitis/diagnóstico , Pancreatitis/epidemiología , Pancreatitis/etiología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Factores de RiesgoRESUMEN
BACKGROUND: The clinical significance of postoperative serum pancreatic enzyme elevation after pancreatoduodenectomy is understudied. We hypothesized that elevation in serum enzymes predicts morbidity and mortality after pancreatoduodenectomy. METHODS: Retrospective review of 677 patients who underwent pancreatoduodenectomy at a single institution from 2013 to 2019. Patients were categorized based on serum enzyme concentrations. Patient characteristics, drain amylase, and outcomes among groups were compared. RESULTS: In total, 415 of 677 patients had postoperative serum amylase concentrations measured. Of these, 243 (59%) were normal, 96 (23%) were classified as postoperative serum hyperamylasemia, and 76 (18%) were classified as postoperative acute pancreatitis. Major morbidity was lower among patients with normal enzyme concentration (10%) and higher in patients with postoperative serum hyperamylasemia (23%) and postoperative acute pancreatitis (18%) (P = .008). Patients with normal enzymes were less likely to develop postoperative pancreatic fistula (5%) compared with patients with postoperative serum hyperamylasemia (26%) and postoperative acute pancreatitis (21%) (P < .001) and less likely to develop delayed gastric emptying (9% vs 23% and 20%, respectively); P = .002. No difference in mortality was seen among groups. CONCLUSION: Elevated serum pancreatic enzyme concentration occurs frequently after pancreatoduodenectomy and is associated with increased postoperative morbidity. Serum enzyme concentration should be considered in management after pancreatoduodenectomy.
Asunto(s)
Hiperamilasemia/epidemiología , Fístula Pancreática/epidemiología , Pancreaticoduodenectomía/efectos adversos , Pancreatitis/epidemiología , Complicaciones Posoperatorias/epidemiología , Anciano , Anciano de 80 o más Años , Amilasas/sangre , Femenino , Mortalidad Hospitalaria , Humanos , Hiperamilasemia/sangre , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Lipasa/sangre , Masculino , Persona de Mediana Edad , Fístula Pancreática/sangre , Fístula Pancreática/diagnóstico , Fístula Pancreática/etiología , Pancreatitis/sangre , Pancreatitis/diagnóstico , Pancreatitis/etiología , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Estudios Prospectivos , Estudios RetrospectivosRESUMEN
OBJECTIVE: The ISGPS aimed to develop a universally accepted definition for PPAP for standardized reporting and outcome comparison. BACKGROUND: PPAP is an increasingly recognized complication after partial pancreatic resections, but its incidence and clinical impact, and even its existence are variable because an internationally accepted consensus definition and grading system are lacking. METHODS: The ISGPS developed a consensus definition and grading of PPAP with its members after an evidence review and after a series of discussions and multiple revisions from April 2020 to May 2021. RESULTS: We defined PPAP as an acute inflammatory condition of the pancreatic remnant beginning within the first 3 postoperative days after a partial pancreatic resection. The diagnosis requires (1) a sustained postoperative serum hyperamylasemia (POH) greater than the institutional upper limit of normal for at least the first 48âhours postoperatively, (2) associated with clinically relevant features, and (3) radiologic alterations consistent with PPAP. Three different PPAP grades were defined based on the clinical impact: (1) grade postoperative hyperamylasemia, biochemical changes only; (2) grade B, mild or moderate complications; and (3) grade C, severe life-threatening complications. DISCUSSIONS: The present definition and grading scale of PPAP, based on biochemical, radiologic, and clinical criteria, are instrumental for a better understanding of PPAP and the spectrum of postoperative complications related to this emerging entity. The current terminology will serve as a reference point for standard assessment and lend itself to developing specific treatments and prevention strategies.
Asunto(s)
Hiperamilasemia , Pancreatitis , Enfermedad Aguda , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Pancreatectomía/efectos adversos , Fístula Pancreática/etiología , Pancreaticoduodenectomía/efectos adversos , Pancreatitis/diagnóstico , Pancreatitis/etiología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , PropilaminasRESUMEN
ABSTRACT: Mortality of critically ill patients with coronavirus disease 2019 (COVID-19) was high. Aims to examine whether time from symptoms onset to intensive care unit (ICU) admission affects incidence of extra-pulmonary complications and prognosis in order to provide a new insight for reducing the mortality. A single-centered, retrospective, observational study investigated 45 critically ill patients with COVID-19 hospitalized in ICU of The Third People's Hospital of Yichang from January 17 to March 29, 2020. Patients were divided into 2 groups according to time from symptoms onset to ICU admission (>7 and ≤7âdays) and into 2 groups according to prognosis (survivors and non-survivors). Epidemiological, clinical, laboratory, radiological characteristics and treatment data were studied. Compared with patients who admitted to the ICU since symptoms onset ≤7âdays (55.6%), patients who admitted to the ICU since symptoms onset >7âdays (44.4%) were more likely to have extra-pulmonary complications (19 [95.0%] vs 16 [64.0%], Pâ=â.034), including acute kidney injury, cardiac injury, acute heart failure, liver dysfunction, gastrointestinal hemorrhage, hyperamylasemia, and hypernatremia. The incidence rates of acute respiratory distress syndrome, pneumothorax, and hospital-acquired pneumonia had no difference between the 2 groups. Except activated partial thromboplastin and Na+ concentration, the laboratory findings were worse in group of time from symptoms onset to ICU admission >7âdays. There was no difference in mortality between the 2 groups. Of the 45 cases in the ICU, 19 (42.2%) were non-survivors, and 16 (35.6%) were with hospital-acquired pneumonia. Among these non-survivors, hospital-acquired pneumonia was up to 12 (63.2%) besides higher incidence of extra-pulmonary complications. However, hospital-acquired pneumonia occurred in only 4 (15.4%) survivors. Critically ill patients with COVID-19 who admitted to ICU at once might get benefit from intensive care via lower rate of extra-pulmonary complications.
Asunto(s)
COVID-19 , Cuidados Críticos , Enfermedad Crítica , Evaluación de Síntomas , Tiempo de Tratamiento/estadística & datos numéricos , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/etiología , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/mortalidad , COVID-19/fisiopatología , China/epidemiología , Cuidados Críticos/métodos , Cuidados Críticos/estadística & datos numéricos , Enfermedad Crítica/mortalidad , Enfermedad Crítica/terapia , Enfermedades del Sistema Digestivo/diagnóstico , Enfermedades del Sistema Digestivo/etiología , Femenino , Neumonía Asociada a la Atención Médica/diagnóstico , Neumonía Asociada a la Atención Médica/mortalidad , Cardiopatías/diagnóstico , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Hipernatremia/diagnóstico , Hipernatremia/etiología , Masculino , Persona de Mediana Edad , Evaluación de Procesos y Resultados en Atención de Salud , Pronóstico , SARS-CoV-2/aislamiento & purificación , Análisis de Supervivencia , Evaluación de Síntomas/métodos , Evaluación de Síntomas/estadística & datos numéricosRESUMEN
BACKGROUND: Postoperative hyperamylasemia is a frequent finding after pancreatoduodenectomy, but its incidence and clinical implications have not yet been analyzed systematically. The aim of this review is to reappraise the concept of postoperative hyperamylasemia with postoperative acute pancreatitis, including its definition, interpretation, and correlation. METHODS: Online databases were used to search all available relevant literature published through June 2019. The following search terms were used: "pancreaticoduodenectomy," "amylase," and "pancreatitis." Surgical series reporting data on postoperative hyperamylasemia or postoperative acute pancreatitis were selected and screened. RESULTS: Among 379 screened studies, 39 papers were included and comprised data from a total of 9,220 patients. Postoperative hyperamylasemia was rarely defined in most of these series, and serum amylase values were measured at different cutoff levels and reported on different postoperative days. The actual levels of serum amylase activity and the representative cutoff levels required to reach a diagnosis of postoperative acute pancreatitis were markedly greater on the first postoperative days and tended to decrease over time. Most studies analyzing postoperative hyperamylasemia focused on its correlation with postoperative pancreatic fistula and other postoperative morbidities. The incidence of postoperative acute pancreatitis varied markedly between studies, with its definition completely lacking in 40% of the analyzed papers. A soft pancreatic parenchyma, a small pancreatic duct, and pathology differing from cancer or chronic pancreatitis were all predisposing factors to the development of postoperative hyperamylasemia. CONCLUSION: Postoperative hyperamylasemia has been proposed as the biochemical expression of pancreatic parenchymal injury related to localized ischemia and inflammation of the pancreatic stump. Such phenomena, analogous to those associated with acute pancreatitis, could perhaps be renamed as postoperative acute pancreatitis from a clinical standpoint. Patients with postoperative acute pancreatitis experienced an increased rate of all postoperative complications, particularly postoperative pancreatic fistula. Taken together, the discrepancies among previous studies of postoperative hyperamylasemia and postoperative acute pancreatitis outlined in the present review may provide a basis for stronger evidence necessary for the development of universally accepted definitions for postoperative hyperamylasemia and postoperative acute pancreatitis.
Asunto(s)
Hiperamilasemia/epidemiología , Fístula Pancreática/epidemiología , Pancreaticoduodenectomía/efectos adversos , Pancreatitis/epidemiología , Complicaciones Posoperatorias/epidemiología , Amilasas/sangre , Amilasas/metabolismo , Diagnóstico Diferencial , Humanos , Hiperamilasemia/sangre , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Incidencia , Páncreas/diagnóstico por imagen , Páncreas/enzimología , Páncreas/cirugía , Fístula Pancreática/sangre , Fístula Pancreática/diagnóstico , Fístula Pancreática/etiología , Pancreaticoduodenectomía/métodos , Pancreatitis/sangre , Pancreatitis/diagnóstico , Pancreatitis/etiología , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Literatura de Revisión como AsuntoRESUMEN
BACKGROUND: Serum amylase activity greater than the institutional upper limit of normal (hyperamylasemia) on postoperative day 0-2 has been suggested as a criterion to define postoperative acute pancreatitis after pancreatoduodenectomy, but robust evidence supporting this definition is lacking. BACKGROUND: To assess the clinical impact of hyperamylasemia after pancreatoduodenectomy and to define postoperative acute pancreatitis. METHODS: Data of 1,235 consecutive patients who had undergone pancreatoduodenectomy between January 2010 and December 2014 were extracted from a prospective database and analyzed. Postoperative acute pancreatitis was defined based on the computed tomography severity index. Logistic regression modeling was used to calculate the postoperative acute pancreatitis rate of the entire study population. RESULTS: Hyperamylasemia on postoperative day 1 was found in 52% of patients after pancreatoduodenectomy. Patients with hyperamylasemia on postoperative day 1 had statistically significantly greater morbidity and mortality than patients with a normal serum amylase activity on postoperative day 1 with the rates of postoperative pancreatic fistula of 14.5% vs 2.1%, and 90-day mortality of 6.6% vs 2.2%, respectively. Of the 364 patients who underwent postoperative computed tomography, 103 (28%) had radiologic signs of acute pancreatitis, thus defining them as having postoperative acute pancreatitis by our definition. Logistic regression modeling showed a 14.7% rate of postoperative acute pancreatitis for the entire patient cohort and 29.2% for patients with hyperamylasemia on postoperative day 1. Outcomes of patients with postoperative acute pancreatitis defined based on the computed tomography severity index showed a rate of postoperative pancreatic fistula of 32.4% and a 90-day mortality rate of 11.8%, which were worse than those of patients with hyperamylasemia on postoperative day 1 alone. CONCLUSION: Hyperamylasemia on postoperative day 1 is a frequent finding after pancreatoduodenectomy, but hyperamylasemia on postoperative day 1 alone is not synonymous with postoperative acute pancreatitis because only 29.2% of such patients have acute pancreatitis based on computed tomography findings. Postoperative acute pancreatitis is a dangerous complication after pancreatoduodenectomy, but its prevalence, according to the gold standard of CT, is not as high as reported previously. Our data suggest that hyperamylasemia on postoperative day 1 and postoperative acute pancreatitis are 2 different entities.
Asunto(s)
Hiperamilasemia/epidemiología , Pancreaticoduodenectomía/efectos adversos , Pancreatitis/epidemiología , Complicaciones Posoperatorias/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Amilasas/sangre , Diagnóstico Diferencial , Femenino , Humanos , Hiperamilasemia/sangre , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Masculino , Persona de Mediana Edad , Páncreas/diagnóstico por imagen , Páncreas/patología , Páncreas/cirugía , Pancreaticoduodenectomía/métodos , Pancreatitis/sangre , Pancreatitis/diagnóstico , Pancreatitis/etiología , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Prevalencia , Estudios Prospectivos , Estudios Retrospectivos , Adulto JovenAsunto(s)
Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Fístula Pancreática/diagnóstico , Fístula Pancreática/etiología , Pancreatitis/diagnóstico , Pancreatitis/etiología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Humanos , Pancreaticoduodenectomía/efectos adversos , Pancreaticoduodenectomía/métodosRESUMEN
PURPOSE: Elucidating the association between pancreatic ductal anomalies and chronic asymptomatic pancreatic hyperenzymemia using magnetic resonance cholangiopancreatography. METHODS: We conducted a single-center, retrospective, case-control study. The healthy community group comprised 554 subjects who participated in a paid, whole-body health checkup program. The patient group comprised 14 subjects with idiopathic pancreatic hyperamylasemia or hyperlipasemia. All subjects underwent magnetic resonance cholangiopancreatography. The clinical features and incidence rates of pancreatic ductal anomalies were then compared between the groups. RESULTS: Compared to the healthy community group, the patient group was significantly more likely to be ≥ age 65 (71.4% of patient group vs. 22.1% of healthy community group), have a history of diabetes mellitus (21.4% vs. 5.4%) or hypertension (35.7% vs. 11.4%), and to have pancreas divisum (21.4% vs. 2.7%), meandering main pancreatic duct (21.4% vs. 4.1%), Wirsungocele (14.3% vs. 1.1%), or dilated main pancreatic duct (14.3% vs. 2.3%). Multivariate analysis found that age ≥ 65 (odds ratio 8.76), presence of pancreas divisum (odds ratio 13.2), meandering main pancreatic duct (odds ratio 8.95), and Wirsungocele (odds ratio 17.6) were independent factors significantly associated with chronic asymptomatic pancreatic hyperenzymemia. CONCLUSIONS: Pancreas divisum, meandering main pancreatic duct, and Wirsungocele were independently associated with chronic asymptomatic pancreatic hyperenzymemia.
Asunto(s)
Pancreatocolangiografía por Resonancia Magnética/métodos , Hiperamilasemia/diagnóstico , Hiperlipidemias/diagnóstico , Enfermedades Pancreáticas/diagnóstico por imagen , Conductos Pancreáticos/anomalías , Conductos Pancreáticos/diagnóstico por imagen , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Páncreas/diagnóstico por imagen , Páncreas/enzimología , Enfermedades Pancreáticas/enzimología , Estudios RetrospectivosRESUMEN
RATIONALE: Reports of malignant ovarian tumor with hyperamylasemia are very rare. We present a patient with hyperamylasemia who was diagnosed with a malignant ovarian tumor. PATIENT CONCERNS: A 46-year-old woman was hospitalized complaining of a 2-day history of abdominal discomfort and fever. On physical examination, she showed abdominal distention and tenderness, with rebound pain. Laboratory evaluation showed significantly elevated serum amylase levels. Computed tomography (CT) revealed a solid mass with uneven density in the pelvis. DIAGNOSES: Based on her clinical symptoms and hyperamylasemia, she was suspected to have acute pancreatitis at first. However, the final pathology showed advanced serous papillary ovarian carcinoma. INTERVENTIONS: She underwent initial therapy for acute pancreatitis, followed by laparotomy once her symptoms had disappeared. A tumor mass with maximum diameter 12âcm was detected originating from the right ovary, and the patient underwent hysterectomy, bilateral salpingo-oophorectomy with omentectomy, and appendectomy. On the 14th day after the surgery, she received 5 courses of chemotherapy with paclitaxel and carboplatin. However, distant metastasis before the 6th course of chemotherapy were detected by CT, she was therefore changed to a chemotherapy regimen containing gemcitabine and capecitabine. OUTCOMES: The final pathology showed advanced serous papillary ovarian carcinoma. On the 14th day after the surgery, she received 5 courses of chemotherapy with paclitaxel and carboplatin. However, her serum CA125 levels rose again before the 6th course of chemotherapy, and CT of the abdomen and pelvis revealed multiple abnormal-density lesions in the peritoneum and pelvic cavity. We considered these to be metastases, and the patient was deemed unresponsive to her previous chemotherapy. She was therefore changed to a chemotherapy regimen containing gemcitabine and capecitabine, and remained on this regimen at the time of writing. LESSONS: Ovarian carcinoma should be considered as a possibility in patients with hyperamylasemia after ruling out other potential common causes. The final diagnosis depends mainly on the clinical manifestation, laboratory results, and CT examination, though pathology is mandatory to confirm the diagnosis. The main treatment is surgical excision.
Asunto(s)
Carcinoma Papilar/complicaciones , Carcinoma Papilar/diagnóstico , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/diagnóstico , Carcinoma Papilar/patología , Carcinoma Papilar/terapia , Diagnóstico Diferencial , Femenino , Humanos , Hiperamilasemia/terapia , Persona de Mediana Edad , Neoplasias Ováricas/patología , Neoplasias Ováricas/terapiaRESUMEN
BACKGROUND Postoperative pancreatitis is one of the most serious complications in endoscopic retrograde cholangiopancreatography (ERCP). To detect potential risk factors for post-ERCP hyperamylasemia and pancreatitis. MATERIAL AND METHODS We reviewed 1786 ERCP procedures in Zhongnan Hospital of Wuhan University from January 2015 to April 2018. Clinical data were extracted, and the complications after ERCP procedures were re-evaluated. Single- and multiple-variable analyses were conducted to detect the potential risk factors. RESULTS We found that 1786 procedures were applied on 1707 patients; 64 patients (3.58%) developed pancreatitis, while asymptomatic hyperamylasemia occurred in 263 cases (14.73%). In multivariate analysis, pancreatic deep wire pass (odds ratio [OR]: 2.280, 95% CI [confidence interval]: 1.129-4.605, P=0.022), endoscopic metal biliary endoprosthesis (OR: 2.399, 95% CI: 1.120-5.138, P=0.024), operation after liver transplantation (OR: 3.057, 95% CI: 1.110-8.422, P=0.031), and fistulotomy (OR: 3.148, 95% CI: 1.036-9.561, P=0.043) were identified as independent risk factors for post-ERCP pancreatitis. Pancreatic deep wire pass (OR: 1.678, 95% CI: 1.136-2.478, P=0.009), fistulotomy (OR: 2.553, 95% CI: 1.096-5.948, P=0.030), and younger age (OR: 0.990, 95% CI: 0.980-0.999, P=0.037) were identified as independent risk factors for hyperamylasemia. CONCLUSIONS To prevent post-ERCP pancreatitis, it is important to avoid high-risk procedures such as fistulotomy and pancreatic deep wire pass, especially in high-risk patients with liver transplantation. For patients with endoscopic metal biliary endoprosthesis, clinicians should pay more attention to the occurrence of post-ERCP pancreatitis.
Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica/efectos adversos , Colangiopancreatografia Retrógrada Endoscópica/métodos , Adulto , Anciano , China , Femenino , Humanos , Hiperamilasemia/complicaciones , Hiperamilasemia/diagnóstico , Masculino , Persona de Mediana Edad , Pancreatitis/diagnóstico , Pancreatitis/etiología , Estudios Retrospectivos , Factores de RiesgoRESUMEN
Postoperative pancreatic fistula (PF) remains one of the most significant complications after pancreaticoduodenectomy (PD). Recently, studies have suggested that post-PD serum hyperamylasemia (HA) may be a risk factor. In this study, we evaluate the relationship of pancreas texture and post-operative serum amylase levels in determining PF risk. This retrospective cohort study evaluated all patients who underwent PD at Thomas Jefferson University from 2009 to 2014. The highest postoperative serum amylase level from postoperative day (POD) 0 to POD 5 was obtained. Chi-square analyses and odds ratio (OR) evaluated the relationship between pancreas texture, serum amylase level, and the development of PF. Data from 524 consecutive patients were analyzed. Serum amylase threshold value of 165 IU/L yielded greatest accuracy from the receiver operating characteristic curve analysis (Sensitivity, 0.70; specificity, 0.72). Grade B or C PF were more common among HA patients (20 vs 3%; P < 0.001). HA was associated with increased rates of PD-associated complications. On multivariable analysis, early postoperative serum HA was more predictive of PF risk (OR, 4.87; P < 0.001) than either pancreatic duct size ≤3 mm (OR, 2.97; P = 0.01) or pancreas texture (OR,1.87; P = 0.05). CONCLUSION: The presence of HA on POD 0 or POD 1 is more predictive than soft pancreas texture or small pancreas duct size alone.
Asunto(s)
Amilasas/sangre , Páncreas/patología , Fístula Pancreática/diagnóstico , Fístula Pancreática/etiología , Pancreaticoduodenectomía/efectos adversos , Complicaciones Posoperatorias/etiología , Anciano , Femenino , Humanos , Hiperamilasemia/complicaciones , Hiperamilasemia/diagnóstico , Masculino , Persona de Mediana Edad , Enfermedades Pancreáticas/sangre , Enfermedades Pancreáticas/complicaciones , Enfermedades Pancreáticas/cirugía , Fístula Pancreática/sangre , Complicaciones Posoperatorias/diagnóstico , Valor Predictivo de las Pruebas , Curva ROC , Estudios RetrospectivosAsunto(s)
Dolor Abdominal/etiología , Ingestión de Alimentos , Cuerpos Extraños/complicaciones , Cuerpos Extraños/diagnóstico , Hiperamilasemia/complicaciones , Hiperamilasemia/diagnóstico , Adulto , Endoscopía del Sistema Digestivo , Cuerpos Extraños/patología , Humanos , Hiperamilasemia/patología , Masculino , Radiografía Abdominal , Tomografía Computarizada por Rayos XRESUMEN
Single-balloon enteroscopy (SBE) is designed for identifying possible small bowel lesions with balloon-assisted enteroscopy that allows deep intubation of the intestine. However, data regarding the outcome and safety of SBE remain limited. We conducted this study to evaluate the outcome and safety of anterograde and retrograde SBE approaches. This retrospective review from a tertiary medical center in Taiwan included endoscopic reports and chart data from 128 patients with 200 anterograde and retrograde procedures from September 2009 to November 2014. In this study, the most common indication for both anterograde and retrograde SBE was obscure gastrointestinal bleeding (64.4% vs. 60.6%). There were no significant differences between anterograde and retrograde approaches in terms of the diagnostic yield (69.3% vs. 52.5%) and intervention rate (23.8% vs. 17.2%). The procedure time was shorter for anterograde SBE than for retrograde SBE (68.1 ± 23.9 vs. 76.8 ± 27.7 min, P = 0.018). In addition, among the subgroup of patients with obscure gastrointestinal bleeding, the most common etiologies for those in different age-groups were angiodysplasia (≥ 65 years), non-specific ulcers (30-64 years), and Meckel's diverticulum (< 30 years). The major complication rate during the study was 1.5%; the rate of asymptomatic hyperamylasemia was higher for patients who underwent anterograde SBE than for those who underwent retrograde SBE (13.9% vs. 2%, P = 0.005). The outcome and safety of anterograde and retrograde SBE are similar. However, anterograde SBE has a shorter procedural time and a higher rate of asymptomatic hyperamylasemia.
Asunto(s)
Angiodisplasia/cirugía , Hemorragia Gastrointestinal/cirugía , Intestino Delgado/cirugía , Divertículo Ileal/cirugía , Úlcera Péptica/cirugía , Enteroscopia de Balón Individual/métodos , Adulto , Anciano , Anciano de 80 o más Años , Angiodisplasia/complicaciones , Angiodisplasia/diagnóstico , Angiodisplasia/patología , Enfermedades Asintomáticas , Femenino , Hemorragia Gastrointestinal/complicaciones , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/patología , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Hiperamilasemia/fisiopatología , Intestino Delgado/irrigación sanguínea , Intestino Delgado/patología , Divertículo Ileal/complicaciones , Divertículo Ileal/diagnóstico , Divertículo Ileal/patología , Persona de Mediana Edad , Seguridad del Paciente , Úlcera Péptica/complicaciones , Úlcera Péptica/diagnóstico , Úlcera Péptica/patología , Estudios Retrospectivos , Enteroscopia de Balón Individual/instrumentación , Taiwán , Centros de Atención Terciaria , Resultado del TratamientoRESUMEN
AIM: To determine the efficacy of rectally administered naproxen for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). METHODS: This double-blind randomized control trial conducted from January 2013 to April 2014 at the Gastrointestinal and Liver Diseases Research Center in Rasht, Iran. A total of 324 patients were selected from candidates for diagnostic or therapeutic ERCP by using the simple sampling method. Patients received a single dose of Naproxen (500 mg; n = 162) or a placebo (n = 162) per rectum immediately before ERCP. The overall incidence of PEP, incidence of mild to severe PEP, serum amylase levels and adverse effects were measured. The primary outcome measure was the development of pancreatitis onset of pain in the upper abdomen and elevation of the serum amylase level to > 3 × the upper normal limit (60-100 IU/L) within 24 h after ERCP. The severity of PEP was classified according to the duration of therapeutic intervention for PEP: mild, 2-3 d; moderate 4-10 d; and severe, > 10 d and/or necessitated surgical or intensive treatment, or contributed to death. RESULTS: PEP occurred in 12% (40/324) of participants, and was significantly more frequent in the placebo group compared to the naproxen group (P < 0.01). Of the participants, 25.9% (84/324) developed hyperamylasemia within 2 h of procedure completion, among whom only 35 cases belonged to the naproxen group (P < 0.01). The incidence of PEP was significantly higher in female sex, in patients receiving pancreatic duct injection, more than 3 times pancreatic duct cannulations, and ERCP duration more than 40 min (Ps < 0.01). There were no statistically significant differences between the groups regarding the procedures or factors that might increase the risk of PEP, sphincterotomy, precut requirement, biliary duct injection and number of pancreatic duct cannulations. In the subgroup of patients with pancreatic duct injection, the rate of pancreatitis in the naproxen group was significantly lower than that in the placebo (6 patients vs 23 patients, P < 0.01, RRR = 12%, AR = 0.3, 95%CI: 0.2-0.6). Naproxen reduced the PEP in patients with ≥ 3 pancreatic cannulations (P < 0.01, RRR = 25%, AR = 0.1, 95%CI: 0.1-0.4) and an ERCP duration > 40 min (P < 0.01, RRR = 20%, AR = 0.9, 95%CI: 0.4-1.2). CONCLUSION: Single dose of suppository naproxen administered immediately before ERCP reduces the incidence of PEP.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Colangiopancreatografia Retrógrada Endoscópica/efectos adversos , Naproxeno/administración & dosificación , Pancreatitis/prevención & control , Dolor Abdominal/etiología , Dolor Abdominal/prevención & control , Administración Rectal , Adulto , Amilasas/sangre , Antiinflamatorios no Esteroideos/efectos adversos , Biomarcadores/sangre , Distribución de Chi-Cuadrado , Colangiopancreatografia Retrógrada Endoscópica/mortalidad , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Hiperamilasemia/prevención & control , Irán , Masculino , Persona de Mediana Edad , Naproxeno/efectos adversos , Oportunidad Relativa , Pancreatitis/diagnóstico , Pancreatitis/etiología , Pancreatitis/mortalidad , Factores de Riesgo , Índice de Severidad de la Enfermedad , Supositorios , Factores de Tiempo , Resultado del Tratamiento , Regulación hacia ArribaRESUMEN
La macroamilasemia debe sospecharse cuando un paciente presenta una concentración catalítica elevada de la α-amilasa plasmática, sin la presencia de datos clínicos que confirmen la existencia de una enfermedad pancreática o parotídea. La macroamilasemia, en la mayoría de los casos, es un complejo formado por la α-amilasa y las inmunoglobulinas plasmáticas que causa una hiperamilasemia con la amilasuria normal o baja. El diagnóstico diferencial con las otras causas de hiperamilasemia es imprescindible para evitar las exploraciones complementarias y los tratamientos invasivos innecesarios. Se presenta el caso de un varón de 53 años con dolor abdominal e hiperamilasemia, diagnosticado inicialmente de pancreatitis aguda. Macroamylasaemia should be suspected when a patient has a high catalytic concentration of plasma α-amylase in the absence of clinical data confirming the existence of a pancreatic or parotid disease (AU)
In most cases, macroamylasaemia is a complex of α-amylase bound to plasma immunoglobulins that cause hyperamylasaemia with low or normal urine amylase. The differential diagnosis with other causes of hyperamylasaemia is essential to avoid unnecessary additional examinations and invasive treatments. The case is presented of a 53 year-old male with abdominal pain and a high plasma amylase, initially diagnosed with acute pancreatitis (AU)
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Hiperamilasemia/diagnóstico , Hiperamilasemia/patología , Dolor Abdominal/complicaciones , Dolor Abdominal/diagnóstico , Dolor Abdominal/etiología , Diagnóstico Diferencial , Electroforesis en Gel de Agar/métodos , Electroforesis en Gel de Agar , Dolor Abdominal/patología , Dolor Abdominal , Pancreatitis/complicaciones , Pancreatitis/patología , Páncreas/patología , Páncreas , alfa-Amilasas/análisis , alfa-Amilasas , ElectroforesisRESUMEN
OBJECTIVES: To assess the relationship between amylase level and small cell lung cancer in a patient with hyperamylasemia of non-pancreatic disease. DESIGN AND METHODS: Case report with correlation analysis between hyperamylasemia and small cell lung cancer while considering immunohistochemistry study and response to chemotherapy. RESULTS: We observed a strong correlation between amylase levels and small cell lung cancer. Immunohistochemistry findings suggested that amylase was produced by the lung cancer in this case. CONCLUSIONS: Amylase can be considered as a tumor marker reflecting response to chemotherapy and disease relapse.
Asunto(s)
Amilasas/análisis , Biomarcadores de Tumor/análisis , Hiperamilasemia/diagnóstico , Neoplasias Pulmonares/enzimología , Carcinoma Pulmonar de Células Pequeñas/enzimología , Antineoplásicos/uso terapéutico , Monitoreo de Drogas , Humanos , Hiperamilasemia/etiología , Hiperamilasemia/metabolismo , Técnicas para Inmunoenzimas , Neoplasias Pulmonares/complicaciones , Masculino , Persona de Mediana Edad , Pronóstico , Carcinoma Pulmonar de Células Pequeñas/complicaciones , Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológicoAsunto(s)
Antineoplásicos/administración & dosificación , Hiperamilasemia , Infiltración Leucémica , Lipasa/sangre , Páncreas , Leucemia-Linfoma Linfoblástico de Células Precursoras , Examen de la Médula Ósea/métodos , Niño , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico/métodos , Humanos , Hiperamilasemia/diagnóstico , Hiperamilasemia/etiología , Infiltración Leucémica/sangre , Infiltración Leucémica/complicaciones , Infiltración Leucémica/diagnóstico , Masculino , Páncreas/diagnóstico por imagen , Páncreas/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras/fisiopatología , Inducción de Remisión/métodos , Tomografía Computarizada por Rayos X/métodos , Ultrasonografía/métodosRESUMEN
Clinical features together with elevation of pancreatic enzymes are the key diagnostic indicators of acute pancreatitis. We report a case of a woman in her 50s who presented with abdominal distension and serum amylase raised to more than 30 times the upper limit of normal. She was initially treated for acute pancreatitis, however, she was not symptomatic of this and the pancreas appeared to be normal on CT scan. Further investigations revealed the patient had a high-grade serous ovarian carcinoma with nodal metastatic spread. An amylase-secreting ovarian tumour was suspected, which was supported by elevated salivary-amylase isoenzymes, consistent with previous reports in the literature. The patient was treated with chemotherapy and surgery, during which her serum amylase and CA-125 initially fell significantly, but eventually both increased, reflecting disease progression. This case serves as an important reminder to consider non-pancreatic causes of raised serum amylase, to avoid misdiagnosis.